Bacterial prostatitis and prostatic fibrosis: modern view on the treatment and prophylaxis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Treatments of chronic bacterial prostatitis (CP) remain difficult problem. Bacterial prostatitis is a disease entity diagnosed clinically and by evidence of inflammation and infection localized to the prostate. Risk factors for UTI in men include urological interventions, such as transrectal prostate biopsy. Ensuing infections after prostate biopsy, such as UTI and bacterial prostatitis, are increasing due to increasing rates of fluoroquinolone resistance. The increasing global antibiotic resistance also significantly affects management of UTI in men, and therefore calls for alternative strategies. Prostatic inflammation has been suggested to contribute to the etiology of lower urinary tract symptoms (LUTS) by inducing fibrosis. Several studies have shown that prostatic fibrosis is strongly associated with impaired urethral function and LUTS severity. Fibrosis resulting from excessive deposition of collagen is traditionally recognized as a progressive irreversible condition and an end stage of inflammatory diseases; however, there is compelling evidence in both animal and human studies to support that the development of fibrosis could potentially be a reversible process. Prostate inflammation may induce fibrotic changes in periurethral prostatic tissues, promote urethral stiffness and LUTS. Patients experiencing CP and prostate-related LUTS could benefit from anti-inflammatory therapies, especially used in combination with the currently prescribed enzyme treatment with Longidase. Treatment results showed that longidase is highly effective in bacterial and abacterial CP. Longidase addition to standard therapeutic methods significantly reduced the disease symptoms and regression of inflammatory-proliferative alterations in the prostate.

Full Text

Restricted Access

About the authors

A. V Zaitsev

SBEI HPE MSMSU n.a. A.I. Evdokimov of RMPH

Email: msmsu@msmsu.ru

D. Yu Pushkar

SBEI HPE MSMSU n.a. A.I. Evdokimov of RMPH

Email: msmsu@msmsu.ru

L. A Khodyreva

Government of Moscow Department of Health «Scientific Research Institute of HealthCare Organization of and Medical Management Moscow Department of HealthCare»

Email: niiozmm@zdrav.mos.ru

A. A Dudareva

Government of Moscow Department of Health «Scientific Research Institute of HealthCare Organization of and Medical Management Moscow Department of HealthCare»

Email: niiozmm@zdrav.mos.ru

References

  1. Заболеваемость взрослого населения России в 2014 году. Статистические материалы. Часть II, III. ФГБУ 23. «Центральный научно-исследовательский институт организации и информатизации здравоохранения» Минздрава России
  2. Кан Д.В., Сегал А.С., Кузьменко А.Н. Диагностика и 24. лечение хронического неспецифического простатита. Методические рекомендации. М., 1980. С. 30
  3. Coyene K.S., Sexton C.C., Thompson C.I. et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009;104:352-360.
  4. Лопаткин Н.А. Руководство по урологии. М., 1998. Т. 2. С. 393-440). 25.
  5. Krieger J.N., Lee S.W., Jeon J., Cheah P.Y., Liong M.L., Riley D.E. Epidemiology of prostatitis. Int J. Antimicrob Agents. 2008;31(Suppl 26. 1):S85-S90.
  6. Pavone-Macaluso M. Chronic Prostatitis Syndrome: A Common, 27. but Poorly Understood Condition. Part I. EAU-EBU Update Series 2007;5:1-15.
  7. Schaeffer A.J., Anderson, Krieger J.N., Lobel, Naber K.G., Nakagawa, Nickel J.C., Nyberg, Weidner W. WHO Consultation, Paris 2005. 28.
  8. Krieger J.N., Nyberg L., Nickel J.C. NIH consensus definition and classification of prostatitis. JAMA. 1999;281:236-237.
  9. Wagenlehner F.M., Naber K.G. Prostatitis: the role of antibiotic treatment. 29. World J. Urol. 2003;21(2):105-108.
  10. Schaeffer A.J., Weidner W., Barbalis G.A. Summary Consensus Statement: Diagnosis and Management of Chronic Prostatitis/Chronic Pelvic Pain 30. Syndrome. Eur Urol. 2003;(Suppl. 2):1-4.
  11. Лоран О.Б., Пушкарь Д.Ю., Сегал А.С., Юдовский С.О. Наше понимание хронического простатита. Фарматека. 2002;10:69-75
  12. Thurmond P., Jing-Hua Yang, Yedan Li, Lerner L.B., Azadzoi K.M. 32. Structural modifications of the prostate in hypoxia, oxidative stress, and chronic ischemia. Korean J. Urol. 2015;56(3): 187-196. doi: 10.4111/ kju.2015.56.3.187. 33.
  13. Кудрявцев Ю.В., Чумаков А.М. Морфологические изменения в предстательной железе при хроническом простатите. Материалы конференции «Современные аспекты диагностики и 34. лечения хронического простатита». Курск, 2000. С. 81-82
  14. Неймарк А.И., Киптилов А.В., Лапий Г.А. Клинические и патоморфологические особенности хронического простатита у рабочих химического производства. Урология. 2015; 35. 6:68-73
  15. Bercovich E., Barabino G., Pirozzi-Farina F., Deriu M. A multivariate analysis of lower urinary tract ageing and urinary symptoms: the role of fibrosis. Archivio italiano di urologia, andrologia: organo ufficiale [di] 36. Societa italiana di ecografia urologica e nefrologica/Associazione ricerche in urologia. 1999;71(5):287-292.
  16. Ma J., Gharaee-Kermani M., Kunju L., Hollingsworth J.M., Adler J., Arruda E.M., Macoska J.A. Prostatic fibrosis is associated with lower urinary tract symptoms. J. Urol. 2012;188(4):1375-1381.
  17. Cantiello F., Cicione A., Salonia A., Autorino R., Tucci L., Madeo I., Damiano R. Periurethral fibrosis secondary to prostatic inflammation causing lower urinary tract symptoms: a prospective cohort study. Urology. 2013;81(5):1018-1023.
  18. Wong L., Hutson P.R., Bushman W. Prostatic Inflammation Induces Fibrosis in a Mouse Model of Chronic Bacterial Infection. PloS one. 2014;9(6):e100770.
  19. Wong L., Hutson P. R., Bushman W. Resolution of chronic bacterial-induced prostatic inflammation reverses established fibrosis. Prostate. 2015;75(1): 23-32. doi: 10.1002/pros.22886.
  20. Vicari E., Calogero A.E., Condorelli R.A., Vicari L.O., La Vignera S. Male accessory gland infection frequency in infertile patients with chronic microbial prostatitis and irritable bowel syndrome: transrectal ultrasound examination helps to understand the links. J Androl. 2012;33(3):404-411. doi: 10.2164/jandrol.111.014654. Epub 2011 Aug 25.
  21. Tsiporenko S.Iu. Influence of Hepatomax on male fertility. Fiziol Zh. 2013;59(3):119-125.
  22. Wolff H. The biologic significance of white blood cells in semen. Fertil Steril. 1995;63(6):1143-1157.
  23. Осадчий А.В., Кульчавеня Е.В. Репродуктивная дисфункция как следствие инфекционно-воспалительных заболеваний. Урология. 2015; 5:104-109
  24. Божедомов В.А., Семенов А.В., Конышев А.В., Липатова Н.А., Пацановская Г.М., Божедомова Г.Е., Третьяков А.В. Репродуктивная функция мужчин при хроническом простатите: клиникоанамнестические и микробиологические аспекты. Урология. 2015; 1:70-78
  25. Sandhu J.S. Prostate Cancer and Chronic Prostatitis. Current Prostate Reports. 2007;5:191-195.
  26. Omabe M., Ezeani M. Infection, inflammation and prostate carcinogenesis. Infection, Genetics and Evolution.2011;11:1195-1198.
  27. De Nunzio C., Kramer G.,Marberger M., Montironi R., Nelson W., SchröderF., Sciarra A., Tubaro A. The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation. Eur Urol. 2011;60(1):106-17. doi: 10.1016/j.eururo.2011.03.055.
  28. Roberts R.O, Bergstralh E.J., Bass S.E., Lieber M.M., Jacobsen S. J. Prostatitis as a Risk Factor for Prostate Cancer. Epidemiology. 2004;15:93-99.
  29. MacLennan G.T., Eisenberg R., Fleshman R.L. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol 2006;176:1012-1016.
  30. DeMarzo A.M., Platz E.A., Sutcliffe S. et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7:256-269.
  31. Perletti G., Montanari E., Vral A., Gazzano G., Marras E., Mione S., Magri V. Inflammation, prostatitis, proliferative inflammatory atrophy: ‘Fertile ground’ for prostate cancer development? Mol Med Rep. 2010;3(1):3-12. doi: 10.3892/mmr_00000211.
  32. Konig J.E., Senge T., Allhoff E.P., Konig W. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 2004;58:121-129.
  33. Konoplia A.I., Teodorovich O.V., Shatohin M.N., Gavriliuk V.P., Mavrin
  34. Аляев Ю.Г., Винаров А.З., Демидко Ю.Л., Спивак Л.Г. Лечение хронического простатита как профилактика возможного развития аденомы предстательной железы. Урология. 2012; 2:39-40
  35. Momozono H., Miyake H., Miyazaki A., Fujisawa M. Significance of urethral fibrosis evaluated by preoperative magnetic resonance imaging as a predictor of continence status after robot-assisted radical prostatectomy. Int J Med Robot. 2015. doi: 10.1002/rcs.1673
  36. Чибичян М.Б, Коган М.И. Лаптева Т.О., Белоусов И.И., Иванов А.Г., Черногубова Е.А. Перипростатическое воспаление как фактор риска развития стеноза везико-уретрального анастомоза после радикальной простатэктомии. Урология. 2015;6:52-57
  37. Пушкарь Д.Ю., Зайцев A.B., Сегал A.C. Лонгидаза в лечении хронического простатита. Урология. 2006;6:26-28
  38. Лоран О.Б., Сегал А.С. Урология. 2001; 5:16-19
  39. Ходырева Л.А., Дударева А.А., Карпов В.К. Лонгидаза в комплексной терапии хронического простатита. Эффективная фармакотерапия. Урология и нефрология. 2014;32(3):24-27
  40. Авдошин В.П., Андрюхин М.И., Михайликов Т.Г. Опыт применения ферментной терапии в комплексном лечении хронического простатита. Consilium medicum. 2008;4:114-117
  41. WHO Drug Information 2015; Volume 29: 3.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies